{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+to+match+ruxolitinib", "query": { "intervention": "Placebo to match ruxolitinib" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 15, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+to+match+ruxolitinib&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-08T20:06:00.567Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01969838", "title": "Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Primary Myelofibrosis", "Post-Polycythemia Vera Myelofibrosis", "Post-Essential Thrombocythemia Myelofibrosis" ], "interventions": [ { "name": "Momelotinib", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Placebo to match momelotinib", "type": "DRUG" }, { "name": "Placebo to match ruxolitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sierra Oncology LLC - a GSK company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 432, "start_date": "2013-12-06", "completion_date": "2019-05-02", "has_results": true, "last_update_posted_date": "2023-05-12", "last_synced_at": "2026-10-08T20:06:00.567Z", "location_count": 11, "location_summary": "Phoenix, Arizona • Escondido, California • Stanford, California + 8 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Escondido", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01969838" }, { "nct_id": "NCT02119676", "title": "Study of Ruxolitinib in Colorectal Cancer Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "CRC (Colorectal Cancer)" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Regorafenib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 396, "start_date": "2014-03", "completion_date": "2016-12", "has_results": true, "last_update_posted_date": "2018-02-13", "last_synced_at": "2026-10-08T20:06:00.567Z", "location_count": 57, "location_summary": "Chandler, Arizona • Gilbert, Arizona • Mesa, Arizona + 54 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02119676" }, { "nct_id": "NCT04896385", "title": "A Study to Evaluate the Mechanism of Action of Ruxolitinib Cream in Subjects With Vitiligo (TRuE-V MOA)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Vitiligo" ], "interventions": [ { "name": "Ruxolitinib cream", "type": "DRUG" }, { "name": "Vehicle Cream", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2021-06-23", "completion_date": "2023-07-10", "has_results": true, "last_update_posted_date": "2025-08-05", "last_synced_at": "2026-10-08T20:06:00.567Z", "location_count": 6, "location_summary": "Fountain Valley, California • Irvine, California • Washington D.C., District of Columbia + 3 more", "locations": [ { "city": "Fountain Valley", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Brooklyn", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04896385" }, { "nct_id": "NCT04921969", "title": "A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Vehicle Cream", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "11 Years", "sex": "ALL", "summary": "2 Years to 11 Years" }, "enrollment_count": 330, "start_date": "2021-07-19", "completion_date": "2024-04-08", "has_results": true, "last_update_posted_date": "2025-03-28", "last_synced_at": "2026-10-08T20:06:00.567Z", "location_count": 64, "location_summary": "Birmingham, Alabama • Hoover, Alabama • Gilbert, Arizona + 49 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Hoover", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04921969" }, { "nct_id": "NCT02119663", "title": "A Study of Ruxolitinib in Pancreatic Cancer Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 86, "start_date": "2014-06", "completion_date": "2016-10", "has_results": true, "last_update_posted_date": "2018-02-13", "last_synced_at": "2026-10-08T20:06:00.567Z", "location_count": 55, "location_summary": "Huntsville, Alabama • Fayetteville, Arkansas • Beverly Hills, California + 52 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02119663" }, { "nct_id": "NCT04603495", "title": "Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Myelofibrosis", "Primary Myelofibrosis", "Post-polycythemia Vera Myelofibrosis", "Post-essential Thrombocythemia Myelofibrosis" ], "interventions": [ { "name": "Pelabresib", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 430, "start_date": "2021-04-09", "completion_date": "2027-06-30", "has_results": true, "last_update_posted_date": "2026-07-17", "last_synced_at": "2026-10-08T20:06:00.567Z", "location_count": 20, "location_summary": "Birmingham, Alabama • Chandler, Arizona • La Jolla, California + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04603495" }, { "nct_id": "NCT04362137", "title": "Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cytokine Storm (Covid-19)" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 432, "start_date": "2020-05-02", "completion_date": "2020-10-17", "has_results": true, "last_update_posted_date": "2021-10-11", "last_synced_at": "2026-10-08T20:06:00.567Z", "location_count": 11, "location_summary": "Fullerton, California • Aurora, Colorado • Denver, Colorado + 8 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Idaho Falls", "state": "Idaho" } ], "official_url": "https://clinicaltrials.gov/study/NCT04362137" }, { "nct_id": "NCT04377620", "title": "Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 211, "start_date": "2020-05-24", "completion_date": "2021-02-26", "has_results": true, "last_update_posted_date": "2022-01-19", "last_synced_at": "2026-10-08T20:06:00.567Z", "location_count": 35, "location_summary": "Scottsdale, Arizona • San Diego, California • Washington D.C., District of Columbia + 29 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Brandon", "state": "Florida" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04377620" }, { "nct_id": "NCT02120417", "title": "A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 149, "start_date": "2014-05", "completion_date": "2017-01", "has_results": true, "last_update_posted_date": "2018-02-13", "last_synced_at": "2026-10-08T20:06:00.567Z", "location_count": 80, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Sedona, Arizona + 77 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Sedona", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02120417" }, { "nct_id": "NCT07357727", "title": "A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Primary Myelofibrosis (PMF)", "Post-polycythemia Vera Myelofibrosis (PPV-MF)", "Post-essential Thrombocythemia Myelofibrosis (PET-MF)" ], "interventions": [ { "name": "Pelabresib", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 460, "start_date": "2026-05-27", "completion_date": "2030-12-27", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-08T20:06:00.567Z", "location_count": 17, "location_summary": "New Haven, Connecticut • Fort Myers, Florida • Jupiter, Florida + 14 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Jupiter", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07357727" } ] }